凯普生物(300639) - 2020 Q3 - 季度财报

Financial Performance - Total assets increased to ¥2,739,214,008.95, representing a growth of 111.20% compared to the end of the previous year[7]. - Net assets attributable to shareholders reached ¥2,348,192,478.21, up 117.08% year-over-year[7]. - Revenue for the reporting period was ¥411,280,826.79, reflecting a 105.01% increase compared to the same period last year[7]. - Net profit attributable to shareholders was ¥144,308,175.17, a significant rise of 219.81% year-over-year[7]. - Basic earnings per share increased to ¥0.68, representing a growth of 223.81% compared to the same period last year[7]. - The weighted average return on equity was 9.33%, an increase from 4.86% in the previous year[7]. - Total operating revenue for Q3 2020 reached ¥411,280,826.79, a significant increase from ¥200,618,974.94 in the same period last year, representing a growth of 105.5%[44]. - Operating profit for the period was ¥179,047,393.85, compared to ¥46,910,695.67 in the previous year, indicating an increase of 281.5%[46]. - Net profit for Q3 2020 was ¥151,307,745.14, up from ¥40,321,221.55 in Q3 2019, reflecting a growth of 274.5%[46]. - Total comprehensive income for the period was ¥298,256,478.64, compared to ¥96,725,015.13 in the previous year, indicating a substantial increase[54]. Cash Flow - Net cash flow from operating activities was ¥79,183,177.38, up 163.98% year-over-year[7]. - Cash received from sales and services increased by 49.57% to ¥720,216,162.35 compared to ¥481,515,447.15 in the same period last year, primarily due to expanded sales scale and increased cash recovery[22]. - Cash received from other operating activities surged by 1,139.95% to ¥28,059,860.37, up from ¥2,262,978.44, mainly due to the recovery of withheld taxes[22]. - The net cash flow from operating activities for Q3 2020 was CNY 121,454,522.72, a significant increase from CNY 50,026,117.52 in Q3 2019, representing a growth of approximately 142.6%[61]. - Total cash inflow from operating activities reached CNY 748,276,022.72, compared to CNY 483,781,895.18 in the same period last year, indicating a year-over-year increase of about 54.9%[61]. - Cash outflow for purchasing goods and services was CNY 212,820,491.05, compared to CNY 77,779,360.96 in Q3 2019, indicating an increase of about 172.5%[61]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,846[11]. - The largest shareholder, Hong Kong Science and Technology Venture Co., Ltd., holds 29.15% of the shares[11]. - The company completed the issuance of 22,945,804 shares to specific investors, with a lock-up period of 6 to 18 months for different shareholders[16]. - The company successfully issued 22,945,804 shares at a price of ¥45.76 per share, raising a total of ¥1,049,999,991.04, with a net amount of ¥1,027,419,602.53 after expenses[24]. Assets and Liabilities - Current assets totaled CNY 2,039,001,503.79, up from CNY 664,630,142.30, indicating a growth of about 207%[36]. - Total liabilities amounted to CNY 252,156,423.26, up from CNY 112,328,167.48, representing an increase of approximately 124%[38]. - Shareholders' equity reached CNY 2,487,057,585.69, compared to CNY 1,184,640,009.97, indicating a growth of about 110%[39]. - The company reported inventory of CNY 43,413,968.27, indicating a significant asset base for operations[68]. Investment and Development - The company has invested CNY 16,849,970.13 in development expenditures, up from CNY 9,393,901.83, reflecting an increase of about 79%[37]. - Research and development expenses for the quarter were ¥17,550,599.39, compared to ¥15,994,988.43 in the previous year, an increase of 9.7%[45]. - The company plans to continue expanding its market presence and investing in new product development[56]. Compliance and Governance - The company has no violations regarding external guarantees during the reporting period[28]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[29]. - The company executed the new revenue recognition standards starting January 1, 2020, which may affect future financial reporting[71]. - The Q3 2020 report was not audited, indicating preliminary financial data[77].